We therefore sought to develop a transgenic model to investigate the pattern of expression of A2AR in the context of anti-tumor immunity and following therapeutic intervention with either immunotherapy, chemotherapy, or cytokines. The gene discussed is ADORA2A; the disease is neoplasm.